[Empagliflozin/linagliptin (type 2 diabetes mellitus) - Benefit assessment according to ยง35a Social Code Book V]

Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018003584
Original Title: Empagliflozin/Linagliptin (Diabetes mellitus Typ 2)
Project Status: Completed
Year Published: 2019
English language abstract: There is no English language summary available
Publication Type: Full HTA
Country: Germany
MeSH Terms
  • Diabetes Mellitus, Type 2
  • Sodium-Glucose Transporter 2 Inhibitors
  • Hypoglycemic Agents
  • Dipeptidyl-Peptidase IV Inhibitors
  • Drug Therapy, Combination
  • Empagliflozin
  • Linagliptin
  • Diabetes Mellitus - Type 2
  • Benefit Assessment
Organisation Name: Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address: IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email: berichte@iqwig.de
Copyright: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.